source
- Nonprofits launch ultra-rare immune disease gene therapy Waskyra at $3.25 million priceTwo nonprofit organizations have received FDA approval for a gene therapy that targets an ultra-rare immune disorder. The therapy, called Waskyra, is now being launched with a list price of $3.25…
- Scynexis secures $214 million BARDA contract to advance oral and IV antifungal SCY-247BARDA awarded Scynexis a $214 million contract to develop a treatment for invasive fungal infections, including an upfront payment of about $18.5 million. The funding will support moving SCY-247,…